外源性酮体与限制碳水化合物饮食对心肌葡萄糖抑制的比较:一项交叉临床试验
酮酯组MGS达标率44%,低于24小时生酮饮食的78%和72小时生酮饮食的83%,未达到非劣效。血清β-羟丁酸(BHB)可强预测MGS(AUROC 0.88),BHB≥0.58可正确分类92%的扫描。
要点
- 酮酯饮料的MGS达标率44%,低于24小时生酮饮食的78%和72小时生酮饮食的83%。
- 血清BHB预测MGS的AUROC为0.88,BHB≥0.58时正确分类92%的扫描。
- 床旁检测设备对BHB的预测价值与实验室检测相当。
核心结论
- 在健康志愿者中,酮酯饮料在实现MGS方面劣于生酮饮食。
- 血清BHB是MGS的高度预测生物标志物,可在18F-FDG PET前临床实施,床旁检测可快速辅助以减少假阳性扫描。
研究设计与样本
- KEETO-CROSS为交叉、非劣效试验,比较生酮饮食(内源性酮症)与酮酯饮料(外源性酮症)。
- 主要终点为PET上实现完全MGS,非劣效界值5%。
- 在生酮饮食完成的37次扫描中分析内源性BHB预测MGS的AUROC(实验室和床旁设备检测)。
主要发现
- 平均年龄30±7岁,50%为女性,45%为非白人。
- 中位BHB水平(mmol/L):酮酯饮料3.82(25th-75th百分位2.55-4.97),24小时生酮饮食0.77(25th-75th百分位0.58-1.02),72小时生酮饮食1.30(25th-75th百分位0.80-2.24)。
- 主要终点达标率:酮酯饮料44%,24小时生酮饮食78%,72小时生酮饮食83%;酮酯 vs 24小时和72小时生酮饮食的非劣效P值分别为0.97和0.98。
- 内源性BHB预测MGS的AUROC为0.88(95% CI 0.71, 1.00)。
- BHB≥0.58可正确分类92%的扫描;床旁设备预测价值相当。
关键数值与推荐
- 非劣效界值为5%。
- MGS达标率:酮酯44%,24小时生酮饮食78%,72小时生酮饮食83%。
- BHB预测MGS的AUROC为0.88(95% CI 0.71, 1.00)。
- BHB≥0.58 mmol/L可正确分类92%的扫描。
临床怎么用
- 血清BHB可用于18F-FDG PET前预测MGS,帮助识别可能假阳性的扫描。
- 床旁BHB检测可快速实施,便于临床流程整合。
- 酮酯饮料不能替代生酮饮食作为MGS准备方案。
局限性
- 研究仅纳入健康志愿者,未在患者中验证。
- 样本量较小,18名完成所有组。
- BHB预测MGS的分析仅基于生酮饮食完成的37次扫描。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ketogenic diet (KD) is the standard of care to achieve myocardial glucose suppression (MGS) for assessing inflammation using 18F-FDG PET. However, failure to suppress physiologic glucose uptake remains a significant diagnostic barrier. Although extending the duration of KD may be effective, exogenously delivered ketones may provide a convenient, reliable, and same-day alternative. The aims of our study were to determine whether exogenous ketone administration is noninferior to the KD to achieve MGS and whether serum β-hydroxybutyrate (BHB) levels can predict MGS. Methods: KEETO-CROSS (Ketogenic Endogenous versus Exogenous Therapies for myoCaRdial glucOse SuppresSion) is a crossover, noninferiority trial of the KD (endogenous ketosis) versus ketone ester ([KE] exogenous ketosis) drink. Twenty healthy participants were enrolled into 3 arms: weight-based KE drink, 24-h KD, and 72-h KD (n = 18 completed all arms). The primary outcome was achievement of complete MGS on PET (noninferiority margin 5%). The area under receiver-operating-characteristics (AUROC) of endogenous BHB levels (analyzed in a laboratory and by point-of-care device) for predicting MGS was analyzed in 37 scans completed on the KD. Results: The mean age was 30 ± 7 y, 50% were women, and 45% were nonwhite. The median achieved BHB levels (mmol/L) were 3.82 (25th-75th percentile, 2.55-4.97) (KE drink), 0.77 (25th-75th percentile, 0.58-1.02) (25th-75th percentile, 24-h KD), and 1.30 (25th-75th percentile, 0.80-2.24) (72-h KD). The primary outcome was achieved in 44% (KE drink), 78% (24-h KD), and 83% (72-h KD) of participants (noninferiority P = 0.97 and 0.98 for KE vs. 24-h and 72-h KD). Endogenous BHB levels robustly predicted MGS (AUROC, 0.88; 95% CI 0.71, 1.00). A BHB of 0.58 or more correctly classified 92% of scans. A point-of-care device provided comparable predictive value. Conclusion: In healthy volunteers, KE was inferior to KD for achieving MGS. Serum BHB is a highly predictive biomarker for MGS and can be clinically implemented upstream of 18F-FDG PET, with rapid facilitation by point-of-care testing, to reduce false-positive scans.
引用
- Selvaraj S, Margulies KB, Dugyala S, et al. Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial. J Nucl Med. 2021. PMID: 34675108. doi:10.2967/jnumed.121.262734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。